PubMed HealthSearch

PubMed · 6428846

Potential medication error with transdermal nitroglycerin.

Abstract

Long-acting nitroglycerin preparations are a mainstay of therapy of angina pectoris. The trademark name of one such preparation led to the incorrect administration of a similarly named scopolamine preparation to a patient with angina. Physicians and pharmacists must be alert to the potential for medication error inherent in the brand names for these two preparations. The case also illustrates other aspects of the proper use of transdermal nitroglycerin patches.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J F Burris. 1984. Potential medication error with transdermal nitroglycerin.. https://doi.org/10.1177/106002808401800605

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Topical glucocorticoids inhibit neurogenic inflammation: involvement of lipocortin 1.

Topical glucocorticoid treatment (betamethasone-17-valerate (0.018 mg/cm2, 3 h pretreatment) significantly inhibited neurogenic oedema formation induced by electrical antidromic stimulation (2 Hz, 15 V, 0.1 ms for 5 min) of the rat saphenous nerve; a response mediated by neuropeptides released from activated capsaicin-sensitive sensory C-fibres. Oedema formation was estimated by measurement of extravasation of i.v. injected 125I-albumin into skin. The inhibitory effect of the topical glucocorticoid was reversed by passive immunisation of rats with polyclonal antibody to the glucocorticoid-inducible anti-inflammatory protein lipocortin 1 (1 ml/kg, s.c., 24 h pretreatment) whilst a non-immune serum was without effect. Similarly the glucocorticoid receptor antagonist RU38486 (20 mg/kg, 2 and 20 h pretreatment) abrogated the response indicating specific binding to glucocorticoid receptors. Topical glucocorticoid treatment also inhibited the oedema produced by intradermal substance P (0.1 nmol) in the dorsal skin of rats. Topical glucocorticoid inhibited neurogenic oedema formation partly through a mechanism dependent upon lipocortin 1. This inhibition may be partly due to a post-junctional effect upon substance P activity/binding however a pre-junctional component cannot be excluded.

Administration, Topical